Program
SRSD107
A development code.
Its studies are mostly in Thrombosis · Coronary Artery Disease · Venous Thromboembolism, led by Sirius Therapeutics.
Furthest: phase 2, since Aug 11, 20254 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sirius Therapeutics | 42 open or running | phase 2since Aug 11, 2025 | Oct 30, 2023 | Dec 2027phase 2 · NCT07318155 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2023First study: phase 1 study in ThrombosisFirst studyNCT06116617 · 40 enrolled · Australia
- Aug 11, 2025Phase 2 study in Venous ThromboembolismNCT07140523 · 450 planned · Czechia
- Dec 7, 2025Phase 2 study in Coronary Artery DiseaseNCT07318155 · 104 planned · China
- Jun 8, 2026Phase 1 study in ThrombosisNCT07655427 · 48 enrolled · China
Ahead
- Dec 2027Primary completion: phase 2 study in Coronary Artery DiseaseNCT07318155
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07655427Thrombosis · China | 1 | Completed | Mar 2, 2025 | 48 |
| NCT07318155Coronary Artery Disease · China | 2 | Recruiting | Dec 2027 | 104 |
| NCT07140523Venous Thromboembolism · Czechia | 2 | Recruiting | Jun 30, 2026 | 450 |
| NCT06116617Thrombosis · Australia | 1 | Completed | Dec 9, 2024 | 40 |
How it is read
Names in the registry
- “SRSD107”, 4 entries
Codes read as this program: SRSD107.
Conditions, from the studies’ own filings
- Thrombosis, 2 studies
- Coronary Artery Disease, 1 study
- Venous Thromboembolism, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.